Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 10/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.66 |
| ▸ | NPC1 | O15118 | 2/20 | 0.61 |
| ▸ | RAB9A | P51151 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15801114 | 0.90 | MAPT (0.71) | MAPTALDH1A1KMT2ANPC1RAB9A | |
| SCHEMBL17669252 | 0.90 | MAPT (0.71) | MAPTALDH1A1KMT2ANPC1RAB9A | |
| SCHEMBL1483566 | 0.85 | MAPT (0.71) | MAPTALDH1A1KMT2ANPC1RAB9A | |
| SCHEMBL3028108 | 0.84 | MAPT (0.69) | MAPTALDH1A1KMT2ANPC1RAB9A | |
| SCHEMBL336009 | 0.83 | NPC1 (0.65) | MAPTALDH1A1KMT2ANPC1RAB9A | |
| SCHEMBL9531913 | 0.83 | NPC1 (0.68) | MAPTALDH1A1KMT2ANPC1RAB9A | |
| SCHEMBL20456544 | 0.83 | MAPT (0.63) | MAPTALDH1A1KMT2ANPC1RAB9A | |
| SCHEMBL909633 | 0.82 | MAPT (0.62) | MAPTALDH1A1KMT2ANPC1RAB9A | |
| SCHEMBL15156349 | 0.82 | MAPT (0.62) | MAPTALDH1A1KMT2ANPC1RAB9A | |
| SCHEMBL1484133 | 0.82 | MAPT (0.67) | MAPTALDH1A1KMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8791102-B2 | Acetanilide sphingosine-1-phosphate receptor antagonists | EXELIXIS, INC. (US) | 2014-07-29 | — | — | US | disclosed |
| US-20110288076-A1 | Sphingosine-1-Phosphate Receptor Antagonists | EXELIXIS, INC. (US) | 2011-11-24 | — | — | US | disclosed |
| EP-2346821-A1 | SPHINGOSINE-1-PHOSPHATE RECEPTOR ANTAGONISTS | Exelixis, Inc. (US) | 2011-07-27 | — | — | EP | disclosed |
| WO-2010045580-A1 | SPHINGOSINE-1-PHOSPHATE RECEPTOR ANTAGONISTS | EXELIXIS, INC. (US) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288076-A1 | Sphingosine-1-Phosphate Receptor Antagonists | S1PR1, S1PR2, S1PR3 | MAPT 4150/4885ALDH1A1 4114/4885KMT2A 3292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.